Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

64.14 -6.67 (-9.42%)

Streaming Delayed Price Updated: 11:48 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble

January 06, 2026

The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation,"...

Via MarketMinute

Why Did ARWR Stock Surge Over 15% Pre-Market Today? ↗

January 06, 2026

The preliminary results from Phase 1/2a clinical trials of the company’s RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients,...

Via Stocktwits

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗

November 26, 2025

Via Stocktwits

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗

September 02, 2025

Via Stocktwits

Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today ↗

November 26, 2025

These are historic days for the company, following its first FDA approval.

Via The Motley Fool

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval ↗

November 25, 2025

Arrowhead Pharmaceuticals exceeded Q4 2025 revenue expectations, driven by its first FDA-approved drug and strong collaborations, marking its shift to a commercial-stage company.

Via Chartmill

Arrowhead (ARWR) Q4 2025 Earnings Call Transcript ↗

November 25, 2025

Arrowhead (ARWR) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗

July 23, 2025

Via Stocktwits

FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗

November 18, 2025

Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.

Via Benzinga

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.

Via Benzinga

Privium Fund Management Sells Into Strength in Pharma Stock ↗

November 04, 2025

Privium Fund Management Sells Into Strength in Pharma Stock

Via The Motley Fool

Topics Regulatory Compliance

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗

September 29, 2025

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

Via Benzinga

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗

September 05, 2025

The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.

Via The Motley Fool

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗

September 02, 2025

Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.

Via Investor's Business Daily

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week ↗

August 14, 2025

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Via Stocktwits

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives ↗

August 14, 2025

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company.

Via Investor's Business Daily

Topics Death

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial ↗

August 14, 2025

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

Via Stocktwits

Arrowhead (ARWR) Q3 2025 Earnings Call Transcript ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

Arrowhead (ARWR) Q3 Revenue Drops 41% ↗

August 07, 2025

Via The Motley Fool

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss ↗

August 07, 2025

Arrowhead Pharmaceuticals reported mixed Q3 2025 results, beating revenue estimates but missing on EPS. Stock fell 5.3% as higher R&D costs widened losses. Key pipeline updates include plozasiran NDA...

Via Chartmill

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? ↗

July 29, 2025

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,...

Via Benzinga

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗

July 28, 2025

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.

Via Benzinga

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗

July 25, 2025

Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.

Via Investor's Business Daily

Topics Death

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗

July 23, 2025

Via Benzinga

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review ↗

July 22, 2025

Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.